EMA: 5 product-specific guidances adopted [BE/BA News]

posted by Helmut Homepage – Vienna, Austria, 2018-08-03 18:52 (2420 d 06:10 ago) – Posting: # 19133
Views: 5,334

Dear all,

today the EMA published another set of product-specific guidances (adopted by the CHMP 26 July, effective with 2 February 2019):
  1. Agomelatine tablet 25 mg
  2. Posaconazole gastro-resistant tablet 100 mg
  3. Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg
  4. Cholic acid capsules 50 mg and 250 mg
  5. Vismodegib hard capsule 150 mg

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,409 posts in 4,921 threads, 1,671 registered users;
18 visitors (0 registered, 18 guests [including 10 identified bots]).
Forum time: 00:03 CET (Europe/Vienna)

There are no such things as applied sciences,
only applications of science.    Louis Pasteur

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5